Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Enlivex ( (ENLV) ) is now available.
Enlivex Therapeutics Ltd. released its unaudited condensed consolidated financial statements for the periods ending September 30, 2025, and 2024. The financial report highlights a decrease in total assets from $27.7 million at the end of 2024 to $20.9 million by September 2025, alongside a net loss of $7.5 million for the nine months ending September 2025. This financial performance reflects ongoing challenges in the company’s operations, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a biotechnology company based in Israel, focusing on the development of innovative immunotherapy treatments. The company is primarily engaged in creating therapies for life-threatening conditions related to the immune system.
Average Trading Volume: 457,703
Technical Sentiment Signal: Sell
Current Market Cap: $24.34M
For detailed information about ENLV stock, go to TipRanks’ Stock Analysis page.